Leicester Research Archive >
College of Medicine, Biological Sciences and Psychology >
MRC Toxicology Unit >
Published Articles, MRC Toxicology Unit >
Please use this identifier to cite or link to this item:
|Title: ||Diminished Sensitivity of Chronic Lymphocytic Leukemia Cells to ABT-737 and ABT-263 Due to Albumin Binding in Blood|
|Authors: ||Vogler, Meike|
Dyer, Martin J.S.
Cohen, Gerald M.
|Issue Date: ||2-Jul-2010|
|Publisher: ||American Association for Cancer Research|
|Citation: ||Clinical Cancer Research, 2010, 16 (16), pp. 4217-4225.|
|Abstract: ||Purpose: Inhibition of the antiapoptotic BCL2 family is one of the most promising areas of anticancer drug development. However, ABT-737, a specific BCL2 inhibitor, is neither orally bioavailable nor metabolically stable. To overcome these problems, the structurally related molecule ABT-263 was synthesized and recently entered clinical trials in hematologic malignancies, including chronic lymphocytic leukemia (CLL). Almost all laboratory studies have been carried out with ABT-737 rather than ABT-263, the drug being used in clinical trials. Currently there are no published data on the comparative effects of these inhibitors. To gain insight into the potential value or limitations of ABT-263 in the clinic, we assessed its ability to induce apoptosis in clinically relevant cellular models of CLL.
Experimental Design: The susceptibility of freshly isolated primary CLL cells to these inhibitors was compared in standard culture conditions and in conditions that more closely mimic in vivo conditions in a whole blood assay system.
Results: ABT-737 was more potent than ABT-263 at inducing apoptosis in CLL cells. In whole blood, ∼100-fold higher concentrations of both drugs were required to induce apoptosis. We found that ABT-263 was highly bound by albumin and that an increased albumin binding of ABT-263 as compared with ABT-737 accounted for the differential sensitivity of CLL cells.
Conclusions: Our data indicate that the exquisite in vitro sensitivity of CLL cells to BCL2 inhibitors may be lost in vivo due to high cell densities and the albumin binding of ABT-263. Modification of ABT-263 may yield a BCL2 inhibitor with greater bioavailability and more favorable pharmacokinetics.|
|Version: ||Post print|
|Status: ||Peer reviewed|
|Rights: ||©2010 American Association for Cancer Research. Deposited with reference to the publisher's archiving policy available on the SHERPA/RoMEO website.|
|Appears in Collections:||Published Articles, MRC Toxicology Unit|
Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.